Context: TSH suppression therapy has been used to decrease thyroid cancer recurrence.
However, validation of effects through studies providing a high level of evidence has been …

Background Thyroid-stimulating hormone (TSH) suppression is recommended for patients
who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of …

Background: Current guidelines recommend against thyrotropin (TSH) suppression in low-
risk differentiated thyroid cancer patients; however, physician practices remain …

Published guidelines on the treatment of thyroid carcinoma support TSH suppressive
therapy as the standard of care for long-term follow-up after initial surgery and sequential …

The ideal therapy for differentiated thyroid cancer is uncertain. Although thyroid hormone
treatment is pivotal, the degree of thyrotropin (TSH) suppression that is required to prevent …

Surgery—with or without postoperative radioiodine—is the standard of care for most patients
with differentiated thyroid carcinoma (DTC). Thyroid hormone replacement therapy is the …

Background: Levothyroxine suppression of thyrotropin (TSH) is broadly applied to patients
with thyroid cancer despite lack of consensus on the optimal TSH concentration necessary …

Background: Thyrotropin (TSH) suppression has improved the clinical outcomes of patients
with differentiated thyroid cancer (DTC). However, the efficacy of TSH suppressive therapy …

BACKGROUND. Long-term thyroid hormone (TH) therapy aiming at the suppression of
serum thyrotropin (TSH) has been traditionally used in the management of well differentiated …

We investigate whether the prognosis of patients with differentiated thyroid cancer is
improved by maintaining a greater level of TSH suppression. One hundred and forty-one …